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Purpose: To define the phenotypic and mutational spectrum of
epilepsies related to DEPDC5, NPRL2 and NPRL3 genes encoding
the GATOR1 complex, a negative regulator of the mTORC1
pathway
Methods: We analyzed clinical and genetic data of 73 novel
probands (familial and sporadic) with epilepsy-related variants in
GATOR1-encoding genes and proposed new guidelines for clinical
interpretation of GATOR1 variants.
Results: The GATOR1 seizure phenotype consisted mostly in focal
seizures (e.g., hypermotor or frontal lobe seizures in 50%), with a
mean age at onset of 4.4 years, often sleep-related and drug-
resistant (54%), and associated with focal cortical dysplasia (20%).
Infantile spasms were reported in 10% of the probands. Sudden
unexpected death in epilepsy (SUDEP) occurred in 10% of the
families. Novel classification framework of all 140 epilepsy-related
GATOR1 variants (including the variants of this study) revealed
that 68% are loss-of-function pathogenic, 14% are likely pathogenic,
15% are variants of uncertain significance and 3% are likely benign.
Conclusion: Our data emphasize the increasingly important role
of GATOR1 genes in the pathogenesis of focal epilepsies (>180
probands to date). The GATOR1 phenotypic spectrum ranges from
sporadic early-onset epilepsies with cognitive impairment comor-
bidities to familial focal epilepsies, and SUDEP.
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INTRODUCTION
Genes encoding components of the amino acid–sensitive
branch of the mechanistic target of rapamycin (mTOR)
signaling pathway were first implicated in familial focal
epilepsies in 2013.1,2 DEPDC5 (DEP domain containing
protein 5), together with NPRL2 and NPRL3 (nitrogen
permease regulator-like 2 and 3) form the GATOR1 (GAP
activity towards rags complex 1) complex, a repressor of the
mechanistic target of rapamycin complex 1 (mTORC1)
pathway.3 Heterozygous germline variants in the GATOR1-
encoding genes (DEPDC5, NPRL2, and NPRL3) are found in
up to 37% of familial focal epilepsies,4 as well as in some cases
with Rolandic epilepsy5 or infantile spasms.6 Mendelian focal
epilepsies caused by variants in GATOR1 genes encompass
familial focal epilepsy with variable foci (FFEVF, MIM
604364),1,2 autosomal dominant nocturnal frontal lobe
epilepsy (ADNFLE, recently renamed sleep-related hypermo-
tor epilepsy [SHE]),7 and familial temporal lobe epilepsy.2
It is noteworthy that malformations of cortical development,
such as focal cortical dysplasia (FCD), occur in some
individuals.8–13 FCD type II, which is characterized by
dysmorphic neurons and balloon cells, is the most common
cause of pediatric drug-resistant epilepsies and represents 9%
of the epilepsy surgery population.14
In this study, we report clinical and molecular genetic
data of a new series of 73 probands with rare variants
in DEPDC5, NPRL2, or NPRL3 genes, the largest
reported so far. We further delineate the GATOR1
phenotype spectrum and provide an updated and critical
review of all novel and previously reported GATOR1
epilepsy-related variants, with new guidance for their clinical
interpretation.
MATERIALS AND METHODS
Patients with GATOR1 variants
Individuals with DEPDC5, NPRL2, or NPRL3 variants
(missense, splice-site/region altering, nonsense, in-frame/
frameshift indels, or copy-number variants [CNVs]) were
referred from diagnostic epilepsy centers in Belgium, Canada,
Denmark, France, Germany, Italy, Switzerland, the Czech
Republic, the Netherlands, the United Kingdom and the
United States. Genomic DNA was extracted from peripheral
blood lymphocytes. Sanger sequencing was used to confirm
single-nucleotide variants, and quantitative polymerase chain
reaction (PCR) to confirm CNVs. All probands and affected
family members underwent detailed clinical examination,
including review of the medical files, magnetic resonance
imaging (MRI), and electroencephalographic (EEG)
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investigations when available. Written informed consent was
obtained from all patients included in the study.
Extraction of variants from the literature
We established a list of all epilepsy-related GATOR1 variants
reported in 24 original publications from PubMed (https://
www.ncbi.nlm.nih.gov/pubmed; accessed September 2017;
Table S2 and Supplementary Information).
Variant annotation and classification
We annotated novel and previously reported variants based on
the longest transcripts of DEPDC5 (Refseq NM_001242896;
NP_001229825), NPRL2 (Refseq NM_006545; NP_006536)
and NPRL3 (Refseq NM_001077350; NP_001070818), using
the online version of Variant Effect Predictor (VEP) for
human GRCh37 (http://grch37.ensembl.org/Homo_sapiens/
Tools/VEP).
Population allele frequencies for each variant were extracted
from the Genome Aggregation Database browser (gnomAD,
http://gnomad.broadinstitute.org/; accessed in July 2017).15
We used in silico prediction tools to assess the pathogeni-
city of variants: M-CAP (Mendelian Clinically Applicable
Pathogenicity) for missense variants;16 and HSF (Human
Splice Finder v3.0) for splice-region variants.
Comparison of GATOR1 variants in epilepsy and gnomAD
cohorts
Coding and splice altering variants in DEPDC5, NPRL2, and
NPRL3 were extracted from the gnomAD database and
annotated using VEP on the transcript of interest. The
distribution of the different types of variants (missense, splice-
site/region altering, nonsense, in-frame/frameshift indels, and
CNVs) and the proportion of M-CAP predicted deleterious
rare missense variants in the gnomAD cohort were then
compared with those found in epilepsy subjects: 110
previously published and 73 from the present cohort.
RESULTS
Clinical features in the new patient cohort
We assembled a cohort of 73 previously unreported probands
with rare variants in DEPDC5, NPRL2, and NPRL3 through
international networking with diagnostic epilepsy centers. The
main clinical features of the 73 probands are presented in
Table 1; the complete clinical description of the 73 probands
(and 26 affected relatives) is presented in Table S1. All
percentages are related to the total number of probands that
could be evaluated for a given feature.
All except two cases (screened for research purposes) were
referred for epilepsy genetic diagnosis. A known family
history of epilepsy was reported in 55% of the probands. The
age at epilepsy onset ranged from the first days of life to 16
years (mean: 4.4 years). Thirty percent (22/73) of the
probands had early-onset epilepsy (≤1 year), among which
focal seizures were reported in 68% (15/22), infantile spasms
in 27% (6/22), or a combination of generalized and focal
seizures in one proband. In the cohort, the seizure spectrum
comprised 36% (26/73) of sleep-related hypermotor seizures,
16% (12/73) of frontal lobe seizures, 32% (23/73) of focal
seizures with undetermined origin, and 10% of infantile
spasms. Seizures occurred predominantly during sleep in 48%
(35/73) of the probands. Interictal epileptiform abnormalities
(sharp waves, spikes or spike-and-waves, focal or multifocal)
were detected by EEG or stereoelectroencephalography
(SEEG) in 83% (55/66) of the probands, and in up to 90%
(18/20) among those affected with SHE. Six other probands
(9%) had interictal focal slow waves, while a normal interictal
EEG was reported in only five probands (7.5%).
Patients were followed up for a period ranging from 8 months
to 2 years (for 6 young probands) up to 58 years (>2 years for 67
probands). Seizure outcome was variable, with a rate of
resistance to antiepileptic drugs (AEDs) of 54% (38/71), and
up to 65% among probands with SHE. Only 11% of probands
were seizure-free on the first AED treatment, while four AEDs
were tested on average. Among the seizure-free patients on
monotherapy, 5/8 received sodium channel–blocking AEDs,
which are classical first-line drugs to treat focal epilepsies. Five
other probands were treated with a ketogenic diet, in addition to
AEDs, with a seizure improvement in two of them.
Neuroimaging investigations, including MRI and
fluorodeoxyglucose-positron emission tomography (FDG-
PET), revealed abnormalities in 38% (27/71) of the probands,
among which 24% (17/71) were malformations of cortical
development. Focal cortical dysplasia (FCD) was diagnosed or
suspected in 20% (14/71) of the probands, a hemispheric
cortical dysplasia in 1 proband, hemimegalencephaly in 1
proband, and focal subcortical heterotopia in another
proband. Four additional probands showed hippocampal
atrophy/sclerosis, and four others had nonspecific brain
abnormalities at MRI (Table S1). FDG-PET showed a focal
hypometabolism with a normal MRI, suggestive of FCD, in
two additional patients.
Epilepsy resective surgery was performed in 11 probands,
including 2 with a normal MRI, and 9 with MRI suggestive of
either FCD (8 probands) or hemimegalencephaly (1 pro-
band). According to the Engel Epilepsy Surgery Outcome
Scale, 60% (6/10) of probands have been seizure-free since
surgery (Engel I score, follow-up range: 9 months to 5 years),
while 20% (2/10) were almost seizure-free (Engel II score,
follow-up: 10 months and 15 months), 1 had a worthwhile
improvement (Engel III score, follow-up: 7 years), and 1 had
no worthwhile improvement (Engel IV score, follow-up: 7
years). Histological examinations confirmed FCD type II in
six probands (five FCD IIa, one FCD IIb) and FCD type I in
two probands.
Cognitive impairment and/or psychiatric comorbidities
were reported in 60% of the probands of this cohort, and in
76% (16/21) if considering only probands with age at onset ≤1
year. Neurocognitive deficits were reported in 44% (30/68) of
the probands. Mild or moderate intellectual disability was
reported in 20% (14/68) and severe in 6% (4/68); language
learning delay was reported in 15% (10/68) and 9% (7/68) had
other cognitive disturbances. In the subgroup of probands
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Table 1 Demographics and clinical features of the 73 probands reported in this study
GATOR1 DEPDC5 NPRL2 NPRL3
Probands 73 63 3 7
Gender (male:female) 36:37 33:30 1:2 2:5
Epilepsy family history 40/73 (55%) 33/63 1/3 6/7
Inheritance
De novo 2/47 (4%) 2/40 0/1 0/6
Inherited 45/47 (96%) 38/40 1/1 6/6
Age at sz onset (years) 4.4 (0–16) 4.4 (0–16) 1.5 (0–3.7) 5.7 (1–16)
Epilepsy phenotype
Sleep-related hypermotor epilepsy 26/73 (36%) 22/63 1/3 3/7
Frontal lobe epilepsy 12/73 (16%) 9/63 1/3 2/7
Temporal lobe epilepsy 1/73 (1%) 1/63 0/3 0/7
Focal epilepsy (unspecified) 23/73 (32%) 21/63 0/3 2/7
Infantile spasms 7/73 (10%) 6/63 1/3 0/7
Generalized epilepsy 3/73 (4%) 3/63 0/3 0/7
Focal febrile seizures 1/73 (1%) 2/63 0/3 0/7
Cognitive comorbidities
Normal 37/68 (54%) 30/59 0/2 7/7
Language delay 10/68 (15%) 9/59 0/2 1/7
Intellectual disability 18/68 (26%) 16/59 2/2 0/7
Other deficits 7/68 (9%) 7/59 0/2 0/7
Psychiatric features
None 37/65 (57%) 30/56 2/2 5/7
ADHD / attention deficit 10/65 (15%) 10/56 0/2 0/7
ASD / autistic features 6/65 (9%) 6/56 0/2 0/7
Oppositional disorder 12/65 (18%) 11/56 0/2 1/7
Anxiety and/or depression 5/65 (8%) 5/56 0/2 0/7
Others 5/65 (8%) 4/56 0/2 1/7
Neuroimaging
Normal 44/71 (62%) 37/61 1/3 6/7
Brain abnormality 27/71 (38%) 24/61 2/3 1/7
Malformations of cortical development 17/27 (63%) 15/24 2/2 0/1
Focal cortical dysplasia 14/27 (52%) 12/24 2/2 0/1
Hemimegalencephaly 1/27 (4%) 1/24 0/2 0/1
Subcortical heterotopia 1/27 (4%) 1/24 0/2 0/1
Hemispheric cortical dysplasia 1/27 (4%) 1/24 0/2 0/1
Hippocampal sclerosis/atrophy 4/27 (15%) 4/24 0/2 0/1
Antiepileptics
Monotherapy 8/72 (11%) 7/62 0/3 1/7
2 Antiepileptic drugs 15/72 (21%) 13/62 0/3 2/7
≥3 Antiepileptic drugs 49/72 (68%) 42/62 3/3 4/7
Good outcome 33/71 (46%) 29/61 0/3 4/7
Drug-resistant 38/71 (54%) 32/61 3/3 3/7
Surgery 11/73 (15%) 9/73 2/3 0/7
Surgery outcome
Engel I 6/10 (60%) 5/8 1/2 0/0
Engel II 2/10 (20%) 2/8 0/2 0/0
Engel III 1/10 (10%) 0/8 1/2 0/0
Engel IV 1/10 (10%) 1/8 0/2 0/0
SUDEPa 9/73 (12%) 8/63 0/3 1/7
Cancer 2/73 (3%) 1/63 0/3 1/7
Sz seizures, ADHD attention-deficit/hyperactivity disorder, ASD autism spectrum disorder, Engel I free of disabling seizures, Engel II rare disabling seizures, Engel III worth-
while improvement, Engel IV no worthwhile improvement
aSUDEP sudden unexpected death in epilepsy cases refer to probands or affected family members
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with age at onset of epilepsy ≤1 year, 20% (4/19) had a severe
intellectual disability or global developmental delay, 8 had a
mild or moderate intellectual disability, and 7 had normal
cognitive function. Psychiatric comorbidities were diagnosed
in 43% (28/65) of the probands: oppositional disorder in 12
probands, attention-deficit hyperactivity disorder (ADHD) or
attention deficit in 10, autism spectrum disorder (ASD)
diagnosis or autistic features in 6, anxiety and/or depression
in 5, disinhibited social engagement disorder in 1, and
obsessive-compulsive disorder in 1.
Because somatic variants in GATOR1-encoding genes
(>400 in DEPDC5, >80 in NPRL2, and >100 in NPRL3 in
the COSMIC database) have been mentioned in various
cancers,3,17 we examined cancer occurrence in epilepsy
probands carrying germline GATOR1 variants. Two probands
developed cancer, one developed Hodgkin lymphoma, and
one developed breast cancer. We could not conclude about a
link between GATOR1 germline variants and increased risk of
cancer.
In this series of 73 families, nine individuals (one proband
and eight affected relatives) succumbed to sudden unexpected
death in epilepsy (SUDEP). SUDEP is a “non-accidental, non-
suicidal and non-drowning death in people with epilepsy,
unrelated to a documented status epilepticus, in which
postmortem examination does not reveal a structural or
toxicologic cause of death.”18,19 According to the SUDEP
classification,19 one proband had a definite SUDEP (con-
firmed by autopsy, which did not reveal a cause of death) and
eight individuals had a probable SUDEP (same definition as
“definite SUDEP,” but without autopsy confirmation). Eight
SUDEP cases belonged to seven families with multiple
affected members in which a pathogenic null variant was
identified in DEPDC5 (two SUDEP cases were in the same
family) and one carried a pathogenic loss-of-function (LoF)
variant in NPRL3 segregating in a large autosomal dominant
SHE family (pedigrees are shown in Fig. S1). Genomic DNA
of 3/9 SUDEP cases, who had a history of sleep-related focal
epilepsy, was available for genetic analysis and confirmed that
these individuals carried the pathogenic variant (the remain-
ing SUDEP cases could not be tested for segregation of the
variants). The mean age at the time of SUDEP was 36.8 years
(age range: 19–59 years).
GATOR1 variants in the new cohort and variant
classification framework
Germline heterozygous variants in GATOR1-encoding genes
were identified in 73 unrelated probands by different
diagnostic targeted gene panels and by exome sequencing
for research purposes in two cases. Variants were inherited in
45 cases and occurred de novo in two probands, while
information was not available in the remaining 26 cases.
Variants were dominantly inherited from an asymptomatic
parent in 64% (29/45) of the probands, illustrating the
reduced penetrance of GATOR1 variants.
Overall, 63 distinct variants were identified: 53 in DEPDC5,
3 in NPRL2, and 7 in NPRL3 (Figs. 1 and 2). Among these, 46
were novel (including 39 single-nucleotide variants and seven
CNVs) and 16 were newly defined as recurrent variants; 34
were LoF variants (nonsense, splice-site, frameshift indels,
and CNVs). According to the new American College of
Medical Genetics and Genomics (ACMG) guidelines for
variant classification of Mendelian disease,20 the 34 newly
reported LoF variants were classified as pathogenic. Moreover,
nonsense-mediated RNA decay (NMD) was previously
suggested for DEPDC5 and NPRL3 transcripts with nonsense
variants, confirming that haploinsufficiency is the pathogenic
mechanism in GATOR1-related disorders.2,7,12,13
Next, we asked whether the remaining 12 novel variants (9
missense, 2 splice-region, and 1 in-frame indel) might be
deleterious. Because of lack of both functional assays and
strong genetic evidence (segregation in more than three
affected family members, or recurrence of a given variant in
unrelated epilepsy probands), these variants would be
classified as variants of uncertain significance (VUS) accord-
ing to the ACMG framework. However, because they are rare
(or absent) in the control population and found in patients
with a phenotype compatible with GATOR1-related focal
epilepsy, we asked whether such variants might nevertheless
be clinically relevant. We therefore propose a new classifica-
tion framework specifically adapted to GATOR1 genes, based
on gnomAD allele frequencies and in silico pathogenicity
predictions (Fig. 3). First, we defined an allele frequency
threshold for likely benign variants, adjusting the BA1 ACMG
rule (which sets the benign classification for variants at an
allele frequency ≥5%, which corresponds to 13,863 alleles in
gnomAD)21 based on the prevalence of GATOR1-related
epilepsies, as recently proposed for MYH7-associated cardi-
omyopathies.22 We estimated the prevalence of genetic focal
epilepsies in the population to be 0.32%, a contribution of
DEPDC5 gene to genetic focal epilepsy of 9.4%23 and a
penetrance of 60%4 and then calculated an allele frequency
threshold of 0.03% for likely benign variants (Supplementary
Information). Therefore, variants with gnomAD allele
frequencies above 0.03% (83 alleles) were classified as likely
benign. Besides, ACMG rules specify that eight alleles should
be considered as the maximum allele count within the
“pathogenic range.”20 We also adjusted this pathogenic range
to reflect the occurrence of LoF variants in GATOR1 genes in
the gnomAD control population. Hence, we set the
pathogenic range allele count of DEPDC5, NPRL2, and
NPRL3 to 6, 3, and 4 alleles in gnomAD, corresponding to
the maximum allele counts of nonsense and frameshift indels
in the gnomAD cohort in each GATOR1 gene. We also used
M-CAP, a novel clinical pathogenicity web-based classifier
that compiles predictions from nine different pathogenicity
prediction tools and conservation scores for missense
variants,16 and HSF to predict the effect of splice-region
variants. Hence, missense and splice-region variants with a
gnomAD frequency within the pathogenic range threshold
and predicted possibly pathogenic by M-CAP or to affect
splicing by HSF were defined as likely pathogenic; otherwise
they were considered as VUS. Finally, as the impact of rare in-
BALDASSARI et al ARTICLE
GENETICS in MEDICINE | Volume 21 | Number 2 | February 2019 401
DEPDC5
Gene
Gene
Gene
Protein
Del ex 1-8
Del ex 2-3
p.Arg165Tyrfs*14
p.Met152Valfs*6
p.Gly142Trpfs*3
p.Tyr127llefs*51
p.Val100Glyfs*3
p.193+1G>A
p.Asn45Glnfs*3
p.Gln107*
c.59-1G>C
p.Tyr7*
Likely
Pathogenic
Likely
Pathogenic
Del ex 1-7
Del ex 5-10
Likely
Benign p.Gln54Pro
p.Val272Leu
c.683+1G>C
p.lle23Asnfs*6
Longin
Longin
TINI
TINI INT CTD
CTD
p.Arg78Cys
p.Arg295*
p.Thr110Ser
p.Leu105Pro
p.Asp214His p.Cys378Trp
p.Thr864Met
p.Trp905Cys
p.Thr1038Asn
p.Ser1073Arg p.Ser1169Arg
p.Ser1162Gly
p.Arg1268Gln
p.Ser1104Leu
p.Ser1154Phe
p.Pro1031His
c.3265-3C>T
c.3563+4A>G
c.3330+5G>C
p.Arg422Gln
p.Gln542Pro
p.Arg485Gln
p.Arg347His
p.Ala928Val
p.Asp967Asn
p.Ala1392Val
p.Arg1586Trp
p.Arg995His
p.Pro357Hisfs*56
p.Trp319Profs*1
p.Ser279Phefs*52
p.Arg165Glyfs*5
p.Gln101*
p.Gln188*
p.Glu249Lys
p.Arg997Cys
p.Thr1081Pro
p.Val1211_Leu1214delinslleHisLeuHis
p.Tyr462Cys
c.1352-4delACAGlnsTGACCCATCC
p.Glu508Argfs*46
p.Tyr519*
p.His214Asp
p.Met181Lys
p.Ser19Thr
p.Tyr281Phe
c.1218-18_1218-15delTGTT
p.Val90lle
c.4033+5A>GVUS
VUS
VUS
NTD SABA SHEN DEP CTDProtein 1
569
3801
Protein 1
Lo
ss
 o
f 
Fu
nc
tio
n
Lo
ss
 o
f 
Fu
nc
tio
n
Lo
ss
 o
f 
Fu
nc
tio
n
M
is
se
ns
e/
sp
lic
e-
re
gi
on
M
is
se
ns
e/
sp
lic
e-
re
gi
on
M
is
se
ns
e/
sp
lic
e-
re
gi
on
1603
p.Phe164del
c.484-1G>A
p.Arg264Glufs*9
p.Asp1565*
p.Trp1558*
p.Gln1536*
p.Gln1523*
p.Gln1016*
p.Tyr920*
c.3021+1G>A
p.Ala951Profs*38
p.Asn315Argfs*4
p.Thr329Leufs*7
p.Val367Glyfs*40
p.Gln797Argfs*18
p.Glu1474Lysfs*100
p.Glu1421Argfs*153
p.Glu1385*
p.Leu1380Argfs*14
p.Leu1344*
p.Ala1396Valfs*78
p.Ala1077Aspfs*82
c.4203+2T>A
c.4520-2A>G
p.Trp1466*
p.lle1148Metfs*24
c.2355-2A>G
p.Arg389Profs*2
p.Leu584Phefs*12
p.Gln465*
p.Gln519*
p.Arg587*
p.Arg615Serfs*47
p.Arg637*
p.Phe467Leufs*51
p.Leu374Phefs*30
p.Tyr306*
p.Asn261Lysfs*11
p.Gln244*
p.Gln176*
c.624+1G>A
p.Arg243*
p.Arg239*
p.Gln140*
p.Trp145*
p.Arg78Glyfs*2
c.279+1G>A
p.Arg1087*
p.Arg874*
p.Trp1369*
p.Arg1332*
p.Arg1268*
p.Arg843*
p.Arg838*
p.Arg328*
p.Arg286*
p.Gln372*
p.Arg422*
p.Arg487*
p.Arg492*
p.Arg555*
NPRL3
NPRL2
c.3696+5G>A
p.Arg34*
p.Arg424*
p.Arg92Gln
p.Ser460Profs*20
p.Ala452Val
p.Asn437Metfs*21
Del ex 8-19
Del ex 31-42
Del ex 40Del ex 28-38
p.Tyr7Cys
Fig. 1 Schematic diagram showing the domain/structural organization of DEPDC5, NPRL2, and NPRL3 proteins and the positions of the 140
distinct epilepsy-related variants reported so far according to the 3D-structure of the GATOR1 protein complex. In the upper panels of each
protein are indicated loss-of-function (LoF) variants, while missense and splice-region variants are shown in the bottom part and classified according to our
novel proposed framework. Recurrent variants are indicated in blue. VUS variant of uncertain significance24
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c.2715G>T (p.Trp905Cys)
c.1134C>G (p.Cys378Trp)
c.1557C>G (p.Tyr519*)
c.683+1G>C (p.?)
c.2783C>T (p.Ala928Val)
c.4175C>T (p.Ala1392Val)
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c.562C>T (p.Gln188*)
c.2989C>T (p.Arg997Cys)
c.3113C>A (p.Thr1038Asn)
c.3507C>G (p.Ser1169Arg)
Fig. 2 All 63 distinct GATOR1 variants identified in the new patient cohort. For missense variants, Mendelian Clinically Applicable Pathogenicity (M-
CAP) was used to predict possible pathogenic (D) or possible benign (B) variants. Human Splice Finder (HSF) v3.0 was used to discriminate splice-region
variants with a possible impact on the splicing (D) and those not predicted to impact the splicing of mRNA (B). cDNA complementary DNA, VUS variant of
uncertain significance, LoF loss of function, N/A not available. Recurrent variants are indicated in blue
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frame indels cannot be predicted by in silico tools, they were
classified as VUS.
In summary, according to this novel classification frame-
work (Fig. 3), six missense and two splice-region variants
were classified as likely pathogenic, while the remaining three
missense variants and the in-frame indel were classified as
VUS (Figs. 1 and 2).
Reclassification of literature-reported GATOR1 variants
We then reviewed the previously published germline epilepsy-
related variants in the three GATOR1 genes. In total, we listed
78 distinct variants in DEPDC5, 7 in NPRL2, and 9 in NPRL3.
Among them, 64% (60/94) were LoF and were classified as
pathogenic, 31% (29/94) were missense, 4% (4/94) were
splice-region variants, and 1 was an in-frame deletion (p.
Phe164del) classified as pathogenic because it segregated in
three large FFEVF families1 and was absent in gnomAD
(Fig. 1, Table S2 and Supplementary Information).
We then applied our classification framework to evaluate
the clinical relevance of the 33 missense/splice-region variants
(Fig. 1 and Table S2). Three missense and one splice-region
variants were classified as likely benign because they were
found at allele counts of 94 (p.Gln54Pro), 118 (p.Ala452Val),
139 (p.Pro1031His), and 181 (c.3265-3C>T) in gnomAD.
Therefore, four previously reported variants are unlikely to be
involved in the pathogenesis of epilepsy. In addition, we
reclassified 12 variants as likely pathogenic and 17 as VUS.
Among the 17 VUS, 7 had already been classified as VUS,
while the remaining 10 had been initially classified as (likely)
pathogenic, mainly because they were absent or rare in the
public databases available at that time (ExAC, EVS, 1000
Genomes). Thanks to the recent high-throughput sequencing
and data aggregation gnomAD initiative, which includes
123,136 exome sequences and 15,496 genome sequences, it
now appears that most of these variants have a frequency
above the pathogenic range, and consequently were reclassi-
fied as VUS. Three variants, rare or absent in gnomAD, were
reclassified as VUS because they were predicted benign by M-
CAP or HSF.
Global GATOR1 mutational spectrum
Overall, 140 distinct GATOR1 variants have been described in
183 epilepsy probands so far. Most variants are LoF (67%),
followed by missense (27%), splice-region variants (4%), and
in-frame indels (1%). Recurrent GATOR1 pathogenic LoF
variants (n= 24) were reported in unrelated cases, indicating
mutational hotspots or founder effects (represented in blue in
Fig. 1 and Table S2). Among the GATOR1 genes, DEPDC5 is
the most frequently mutated gene accounting for 85% (155/
183) of all cases (Fig. 4). This may be explained by the greater
length of DEPDC5 transcript (5551 bp) compared with
NPRL2 (1700 bp) and NPRL3 (2881 bp), and the fact that
NPRL2 and NPRL3 have been tested in a lower number of
individuals due to their more recent discovery.
We then compared the type of variants among the 140
epilepsy-related GATOR1 variants with those listed in
gnomAD. Excluding silent variants, the distribution of
GATOR1 variants in gnomAD was 80% missense, 15%
splice-region variants, 4% LoF, 1% in-frame indels, and was
similar for all three GATOR1 genes (Fig. S2). This contrasts
with the epilepsy cohort, in which a predominance of LoF
variants is observed (67% as a mean among all GATOR1
genes, Fig. S2). As expected, this enrichment of LoF variants
in the epilepsy patient’s cohort is consistent with the
presumed role of these variants in the pathogenesis of
epilepsy. Nonetheless, the presence of rare LoF variants in
gnomAD is likely to reflect the reduced penetrance and
milder presentations observed in GATOR1 families.4 As
expected, the percentage of individuals with likely pathogenic
missense variants in DEPDC5 and NPRL2 genes was
significantly higher in the epilepsy cohort compared with
the gnomAD cohort (47% vs. 1.7% for DEPDC5 [p value
<2.2e−16], and 40% vs. 4.7% for NPRL2 [p value= 0.02], two-
tailed Fisher’s exact test). This result confirms that the hereby
proposed classification method is a valuable resource to help
discriminate likely pathogenic and likely benign variants
identified in GATOR1 genes.
The architecture of GATOR1 protein complex was recently
solved by cryo-electron microscopy, revealing five protein
GATOR1
Coding / Splice-
region variants
GnomAD
allele frequency
≥0.03%
<0.03%
Likely benign
Possibly benign
Possibly pathogenic
Missense / 
Splice-region
Missense
In-frame
indel
LoF Pathogenic
Likely pathogenic
Likely pathogenic
VUS
VUS
VUS
VUS
>Pathogenic rangeGnomAD
allele count
≤Pathogenic range
Splice-region
HSF prediction
M-CAP prediction
Neutral
Splicing affecting
Fig. 3 Classification framework for epilepsy-related GATOR1 var-
iants. Pathogenic range: 6 alleles for DEPDC5, 3 alleles for NPRL2, and 4
alleles for NPRL3
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domains in DEPDC5: N-terminal domain (NTD), structural
axis for binding arrangement (SABA) domain, steric hin-
drance for enhancement of nucleotidase activity (SHEN)
domain, DEP domain, and C-terminal domain (CTD).24 We
analyzed the distribution of the 31 missense variants along the
different DEPDC5 domains but did not find any significant
clustering (Fig. S3, Supplementary Information).
DISCUSSION
With over 180 unrelated families described to date, genes of
the GATOR1-mTORC1 pathway (DEPDC5, NPRL2, and
NPRL3) are collectively the most frequently mutated genes in
focal epilepsies, among which DEPDC5 is predominantly
found (85% of all cases).
We reviewed the clinical features of all 183 GATOR1
probands reported so far (in the literature and in this study).
As the phenotype is similar between individuals carrying
variants in DEPDC5, NPRL2 or NPRL3 (Supplementary
Information, Table S2), we define a “GATOR1” phenotype.
The GATOR1-related epilepsy phenotype consists mostly in
SHE (characterized by sleep-related focal hypermotor sei-
zures), accounting for 25% (45/183) of all cases; other focal
epilepsies (including frontal, temporal, frontotemporal, occi-
pital, parietal, centrotemporal epilepsies) have been described
in 54% (93/172) of the cases, while FFEVF was diagnosed in
9% (16/183). Infantile spasms were also part of the GATOR1
phenotype spectrum, occurring in 6.6% (12/183) of all
reported GATOR1-mutated patients (including the study by
Carvill et al.6). Drug resistance in this novel series was
observed in half of the probands, and up to 65% in probands
with SHE, supporting previous studies based on smaller
cohorts of families with SHE/ADNFLE (7/9 drug-resistant
individuals)7 or infantile spasms (4/5)6. Malformations of
cortical development (mostly FCD) were reported in 24% of
the probands. A good surgery outcome (Engel scores I–II) was
achieved in 80% of them. Previous studies also reported
favorable surgery outcome in FCD cases with variants in
GATOR1 genes, with seizure remission in six individuals and
a worthwhile improvement in three others,9,12,13 indicating
that the presence of a germline GATOR1 variant does not
represent a contraindication for surgery. In one patient with
an inherited DEPDC5 variant who underwent epilepsy
surgery (proband 14), a somatic second-hit variant, in trans
configuration, was detected in the DNA extracted from the
resected epileptogenic zone, suggesting that a loss-of-function
biallelic mutational mechanism in a negative regulator of
mTORC1 causes FCD.25 In this study, cognitive impairment
and/or psychiatric comorbidities were commonly reported
(60% of the probands), although severe cognitive impairment
occurred only in early-onset cases, mostly presenting with
infantile epileptic spasms. Previous studies also mentioned
neuropsychiatric comorbidities in ~36% of the probands with
GATOR1 variants (Table S2). The higher percentage reported
in this study may reflect the inclusion of a greater number of
individuals (30%) with early-onset epilepsy (≤1 year), which is
classically associated with intellectual disability,26 and may
therefore reflect a bias due to the fact that younger and more
severely affected patients are more often referred for
molecular diagnosis. Moreover, ASD was diagnosed in 9%
of the probands of this series, confirming a recent study
reporting a DEPDC5 variant (p.Tyr1546His) in a patient with
ASD and frontal epileptiform discharges but no clinical
seizures.27
Here, we reported nine SUDEP cases among the 73 new
families; two were part of the same family. Two previous
studies have described SUDEP cases among three families
with inherited DEPDC5, NPRL2, or NPRL3 variants.13,28
Moreover, in a retrospective SUDEP cohort, DEPDC5 variants
were found in ~10% (6/61) of cases.29 Overall, SUDEP cases
were reported in 17 families over 183 (9.3%), emphasizing a
possible increased risk of SUDEP in individuals with
GATOR1 variants when compared with the global incidence
of SUDEP of 0.22/1000 individuals/year in children and
1.2/1000 individuals/year in adults with epilepsy.30 The early
age at onset of epilepsy, drug resistance, and predominant
sleep-related occurrence of seizures observed in GATOR1-
mutated patients, are well-recognized SUDEP risk factors.18,19
However, like SCN1A variants in Dravet syndrome, GATOR1
variants might confer a higher risk for SUDEP by themselves,
although the GATOR1-related physiopathological mechan-
isms of SUDEP remain unknown so far.31 Assessing whether
GATOR1 variants increase SUDEP risk via direct effects on
cardiorespiratory functions may have profound clinical
impact.
Finally, we attempted to identify genotype–phenotype
correlations among the 183 cases and asked whether
pathogenic LoF variants might cause a more severe phenotype
with FCD, SUDEP, or infantile spasms than likely pathogenic/
VUS variants. We reviewed the literature and this study, and
found that 28/32 patients with FCD, 15/17 SUDEP families,
and 9/11 with infantile spasms had a pathogenic LoF variant
(Table S2). We did not disclose any statistically significant
genotype–phenotype correlation.
All GATOR1 variants
(n=140, 183 cases)
11%
(18 cases)
6%
(10 cases)
83%
(155 cases)
DEPDC5 NPRL2 NPRL3
Fig. 4 Distribution of the 140 distinct epilepsy-related GATOR1 var-
iants among the 183 probands reported so far. Percentages and
number of probands are indicated for each gene
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The assignment of pathogenicity of LoF variants (repre-
senting 67% of all epilepsy-related GATOR1 variants) is
straightforward because haploinsufficiency has been shown to
be the pathogenic mechanism.2,7,12,13 However, the puzzling
and unanswered question is whether the 31% of rare missense
or splice-region variants have a clinical significance. Several
obstacles are: (1) the lack of functional evidence to prove
deleterious effect on protein function; (2) the lack of a strong
segregation support, and incomplete penetrance (with var-
iants inherited from asymptomatic parents in 64% of the
cases); and (3) the absence of recurrent missense variants
(except for the p.Arg92Gln variant in NPRL3) as shown for
LoF variants (suggesting mutational hotspots). To respond to
an important need for diagnostic testing, we adapted the
ACMG classification to GATOR1-related epilepsies, to
provide an updated variant classification framework for
clinical interpretation. Considering that the frequency of a
given variant in the general population is to date the most
reliable criterion for interpreting its clinical significance, we
took advantage of the recent release of gnomAD to classify all
epilepsy-related GATOR1 variants using a threshold specifi-
cally dedicated to GATOR1-related epilepsies. Our classifica-
tion framework together with an accurate delineation of the
GATOR1 phenotype spectrum will help clinicians and
geneticists for the clinical interpretation of GATOR1 variants.
While none of the missense/splice-region variants was
classified as pathogenic according to our framework, future
in vitro functional assays aimed to measure mTORC1 activity
should allow to definitively settle on their pathogenicity.
To conclude, this collaborative study emphasizes that
GATOR1 genes of the amino acid–sensing branch of the
mTORC1 pathway, especially DEPDC5, are key contributors
to a broad spectrum of lesional and nonlesional epilepsies,
with variable but highly consistent phenotypes. The patho-
genic molecular mechanism linked to GATOR1 haploinsuffi-
ciency is a hyperactivation of mTORC1 pathway, as shown in
human resective brain specimens12,13 and rodent models.32–34
However, how this signaling cascade alters neuronal network
function, neuronal development, and ultimately leads to
seizures remains to be elucidated. While a high rate of drug
resistance to traditional AEDs is often reported, this study
also points out a favorable epilepsy surgery outcome in some
cases. For patients who are not eligible for surgery, alternative
therapeutic approaches targeting GATOR1/mTORC1 com-
plexes are urgently needed. Currently available mTORC1
inhibitors, such as rapamycin, represent promising drugs in
the treatment of focal epilepsies.35 Yet, selective agonists of
GATOR1 could act as antiepileptogenic drugs as well, which
could ultimately lead to reduced side effects and a targeted
therapy.
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